|
||
|
|
|
||
|
|
This Figure summarizes the most recent ACCF/AHA/ESC and ACCF/AHA/HRS guidelines and recommendations for anticoagulation in patients with AFib and consequently at risk for stroke. Very succinctly, these guidelines mandate that patients with moderate risk factors warrant more aggressive anticoagulation, which means either with warfarin or with one of the new oral anticoagulation agents, whereas those patients with no risk factors will usually have no therapy or merely antiplatelet therapy with aspirin.[49] [50]
Rothman SA. Am J Med 2013; 126: 00-00.
[ACCF = American College of Cardiology Foundation; AHA = American Heart Association; ESC = European Society of Cardiology; HRS = Heart Rhythm Society]
[49] Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS Focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57:e101-e198.
[50] Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011;57:1330-1337.